P3 Health Partners (PIII) Set to Announce Earnings on Monday

P3 Health Partners (NASDAQ:PIII) is projected to issue its Q3 2026 results after the market closes on Monday, November 9th. Analysts expect P3 Health Partners to post earnings of ($3.9650) per share and revenue of $384.95 million for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Monday, November 9, 2026 at 4:30 PM ET.

P3 Health Partners (NASDAQ:PIII) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.89) by $1.26. The firm had revenue of $386.38 million for the quarter, compared to analyst estimates of $377.80 million.

P3 Health Partners Stock Up 4.2%

PIII traded up $0.17 during trading on Monday, hitting $4.20. The company had a trading volume of 213 shares, compared to its average volume of 418,325. The company has a market capitalization of $30.49 million, a PE ratio of -0.13 and a beta of 1.81. P3 Health Partners has a one year low of $1.52 and a one year high of $16.89. The firm’s 50-day moving average price is $6.74 and its 200 day moving average price is $6.55.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on PIII shares. Lake Street Capital restated a “buy” rating and issued a $23.00 target price on shares of P3 Health Partners in a research report on Tuesday, August 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of P3 Health Partners in a research report on Tuesday, August 25th. One research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $17.00.

Insider Transactions at P3 Health Partners

In other P3 Health Partners news, major shareholder Hudson Vegas Investment Spv, L sold 50,000 shares of the business’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $16.48, for a total value of $824,000.00. Following the completion of the sale, the insider directly owned 48,959 shares of the company’s stock, valued at $806,844.32. The trade was a 50.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 10.86% of the stock is currently owned by company insiders.

P3 Health Partners Company Profile

P3 Health Partners Inc is a physician-led healthcare company focused on value-based care for Medicare Advantage beneficiaries. The company works with primary care physicians, specialists, health plans and community organizations to coordinate care and improve health outcomes while addressing patients’ medical and social needs.

Its services include primary care support, care coordination, chronic-condition management, preventive care, medication management and patient navigation. P3’s model uses an integrated care team and data-driven clinical programs to help physicians manage the health of senior populations across the care continuum.

Founded in 2017, P3 Health Partners became a publicly traded company in 2021 through a business combination with Foresight Acquisition Corp.